US23306J1016 - ADR
DBV TECHNOLOGIES SA-SPON ADR
NASDAQ:DBVT (5/2/2024, 11:57:13 AM)
0.68
-0.01 (-1.45%)
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The company is headquartered in Montrouge, Ile-De-France and currently employs 88 full-time employees. The company went IPO on 2012-03-29. The firm's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. The company dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The firm's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The firm operates one subsidiary DBV Technologies Inc. in the United States.
DBV TECHNOLOGIES SA-SPON ADR
177-181 avenue Pierre Brossolette
Montrouge ILE-DE-FRANCE 92120
P: 33155427878
CEO: Daniel Tasse
Employees: 88
Website: https://www.dbv-technologies.com/
Châtillon, France, April 25, 2024 Combined General Meeting of May 16, 2024 Procedures for Obtaining Information and Preparatory Documents for the...
Châtillon, France, le 25 avril 2024 Assemblée Générale Mixte du 16 mai 2024 Modalités de mise à disposition des informations et documents préparatoires à...
...
Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 mars 2024 (Article 223-16 du Règlement Général de...
Here you can normally see the latest stock twits on DBVT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: